according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Lynestrenol Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 4.2
 06.04.2024
 462442-00018
 Date of first issue: 15.01.2016

### SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name : Lynestrenol Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-

stance/Mixture

: Pharmaceutical

Recommended restrictions

on use

Not applicable

1.3 Details of the supplier of the safety data sheet

Company : Organon & Co.

30 Hudson Street, 33nd floor

07302 Jersey City, New Jersey, U.S.A

Telephone : +1-551-430-6000

E-mail address of person

responsible for the SDS

: EHSSTEWARD@organon.com

### 1.4 Emergency telephone number

+1-215-631-6999

### **SECTION 2: Hazards identification**

### 2.1 Classification of the substance or mixture

### Classification (REGULATION (EC) No 1272/2008)

Germ cell mutagenicity, Category 1B H340: May cause genetic defects. Carcinogenicity, Category 2 H351: Suspected of causing cancer.

Reproductive toxicity, Category 1A H360Fd: May damage fertility. Suspected of dam-

aging the unborn child.

Specific target organ toxicity - repeated

exposure, Category 2

H373: May cause damage to organs through pro-

longed or repeated exposure.

### 2.2 Label elements

### Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms

Signal word : Danger

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Lynestrenol Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 4.2
 06.04.2024
 462442-00018
 Date of first issue: 15.01.2016

Hazard statements : H340 May cause genetic defects.

H351 Suspected of causing cancer.

H360Fd May damage fertility. Suspected of damaging

the unborn child.

H373 May cause damage to organs through prolonged or

repeated exposure.

Precautionary statements : Prevention:

P201 Obtain special instructions before use.

P260 Do not breathe dust.

P280 Wear protective gloves/ protective clothing/ eye protec-

tion/ face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/

attention.

Storage:

P405 Store locked up.

Hazardous components which must be listed on the label:

Lynestrenol

EUH208 Contains Tocopherol. May produce an allergic reaction.

### 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

### **SECTION 3: Composition/information on ingredients**

### 3.2 Mixtures

### Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Lynestrenol	52-76-6	Acute Tox. 4; H302	>= 1 - < 10

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Lynestrenol Formulation**

Version 4.2	Revision Date: 06.04.2024	SDS Number: 462442-00018	Date of last issue: 30.09.2023 Date of first issue: 15.01.2010	
		200-151-4	Muta. 1B; H340 Carc. 2; H351 Repr. 1A; H360Fd STOT RE 1; H372 (Blood, Mammary gland, Uterus (in- cluding cervix), Ovary)	
Toco	pherol	10191-41-0 233-466-0	Skin Sens. 1B; H317	>= 0,1 - < 1

For explanation of abbreviations see section 16.

### **SECTION 4: First aid measures**

### 4.1 Description of first aid measures

General advice : In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

Protection of first-aiders : First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled : If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty

of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact : If in eyes, rinse well with water.

Get medical attention if irritation develops and persists.

If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water.

### 4.2 Most important symptoms and effects, both acute and delayed

Risks : May cause genetic defects.

Suspected of causing cancer.

May damage fertility. Suspected of damaging the unborn

child.

May cause damage to organs through prolonged or repeated

exposure.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Lynestrenol Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 4.2
 06.04.2024
 462442-00018
 Date of first issue: 15.01.2016

Contact with dust can cause mechanical irritation or drying of

the skin.

Dust contact with the eyes can lead to mechanical irritation.

May produce an allergic reaction.

### 4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

### **SECTION 5: Firefighting measures**

### 5.1 Extinguishing media

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

### 5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-

fighting

Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a

potential dust explosion hazard.

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod: :

ucts

Carbon oxides

### 5.3 Advice for firefighters

Special protective equipment :

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

### **SECTION 6: Accidental release measures**

### 6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Lynestrenol Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 4.2
 06.04.2024
 462442-00018
 Date of first issue: 15.01.2016

### 6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

### 6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Sweep up or vacuum up spillage and collect in suitable con-

tainer for disposal.

Avoid dispersal of dust in the air (i.e., clearing dust surfaces

with compressed air).

Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

### 6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

### **SECTION 7: Handling and storage**

### 7.1 Precautions for safe handling

Technical measures : Static electricity may accumulate and ignite suspended dust

causing an explosion.

Provide adequate precautions, such as electrical grounding

and bonding, or inert atmospheres.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust

ventilation.

Advice on safe handling : Do not get on skin or clothing.

Do not breathe dust. Do not swallow.

Avoid contact with eyes.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Keep container tightly closed.

Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition.

Take precautionary measures against static discharges. Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the

environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Lynestrenol Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 4.2
 06.04.2024
 462442-00018
 Date of first issue: 15.01.2016

flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contami-

nated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

### 7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers

Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national

regulations.

Advice on common storage : Do not store with the following product types:

Strong oxidizing agents

Self-reactive substances and mixtures

Organic peroxides

Explosives Gases

7.3 Specific end use(s)

Specific use(s) : No data available

### **SECTION 8: Exposure controls/personal protection**

### 8.1 Control parameters

### **Occupational Exposure Limits**

Dust 5 mg/m3

Value type (Form of exposure): TWA (respirable dust)

Basis: FOR-2011-12-06-1358

10 mg/m3

Value type (Form of exposure): TWA (total dust)

Basis: FOR-2011-12-06-1358

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Lynestrenol	52-76-6	TWA	1 μg/m3 (OEB 4)	Internal
		Wipe limit	10 μg/100 cm <sup>2</sup>	Internal
Talc	14807-96-6	TWA (respirable dust)	2 mg/m3	FOR-2011- 12-06-1358
		TWA (total dust)	6 mg/m3	FOR-2011- 12-06-1358

### Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006:

Substance name	End Use	Exposure routes	Potential health effects	Value
Glycerine	Workers	Inhalation	Long-term local ef-	56 mg/m3

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Lynestrenol Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 4.2
 06.04.2024
 462442-00018
 Date of first issue: 15.01.2016

			fects	
	Consumers	Ingestion	Long-term systemic effects	229 mg/kg bw/day
	Consumers	Inhalation	Long-term local ef- fects	33 mg/m3
Tocopherol	Workers	Inhalation		44 mg/m3
	Workers	Skin contact		125 mg/kg bw/day
	Consumers	Inhalation		10,8 mg/m3
	Consumers	Skin contact		62,5 mg/kg bw/day
	Consumers	Ingestion		6,25 mg/kg bw/day

### Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:

Substance name	Environmental Compartment	Value
Glycerine	Fresh water	0,885 mg/l
	Marine water	0,0885 mg/l
	Intermittent use/release	8,85 mg/l
	Sewage treatment plant	1000 mg/l
	Fresh water sediment	3,3 mg/kg dry weight (d.w.)
	Marine sediment	0,33 mg/kg dry weight (d.w.)
	Soil	0,141 mg/kg dry weight (d.w.)

### 8.2 Exposure controls

### **Engineering measures**

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., vacuum conveying from a closed system, packout head with inflatable seal from stationary container, ventilated enclosure, etc.).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Essentially no open handling permitted.

Use closed processing systems or containment technologies.

### Personal protective equipment

Eye/face protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Lynestrenol Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 4.2
 06.04.2024
 462442-00018
 Date of first issue: 15.01.2016

being performed (e.g., sleevelets, apron, gauntlets, disposable

suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection. Equipment should conform to NS EN 14387

Filter type : Combined particulates and organic vapour type (A-P)

### **SECTION 9: Physical and chemical properties**

9.1 Information on basic physical and chemical properties

Physical state : powder

Colour : No data available

Odour : No data available

Odour Threshold : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flammability (solid, gas) : May form explosive dust-air mixture during processing, han-

dling or other means.

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Flash point : Not applicable

Auto-ignition temperature : No data available

Decomposition temperature : No data available

pH : No data available

Viscosity

Viscosity, kinematic : Not applicable

Solubility(ies)

Water solubility : No data available

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Lynestrenol Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 4.2
 06.04.2024
 462442-00018
 Date of first issue: 15.01.2016

Partition coefficient: n-

octanol/water

: Not applicable

Vapour pressure : Not applicable

Relative density : No data available

Density : No data available

Relative vapour density : Not applicable

Particle characteristics

Particle size : No data available

9.2 Other information

Explosives : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Evaporation rate : Not applicable

### **SECTION 10: Stability and reactivity**

### 10.1 Reactivity

Not classified as a reactivity hazard.

### 10.2 Chemical stability

Stable under normal conditions.

### 10.3 Possibility of hazardous reactions

Hazardous reactions : May form explosive dust-air mixture during processing, han-

dling or other means.

Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : Heat, flames and sparks.

Avoid dust formation.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

### 10.6 Hazardous decomposition products

No hazardous decomposition products are known.

### **SECTION 11: Toxicological information**

### 11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Lynestrenol Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 4.2 06.04.2024 462442-00018 Date of first issue: 15.01.2016

Information on likely routes of: Inhalation Skin contact exposure

Ingestion Eye contact

**Acute toxicity** 

Not classified based on available information.

**Product:** 

Acute oral toxicity Acute toxicity estimate: > 2.000 mg/kg

Method: Calculation method

**Components:** 

Lynestrenol:

Acute oral toxicity : LD50: > 1.000 - 8.000 mg/kg

Acute toxicity (other routes of : LD50 (Mouse): 110 mg/kg

administration)

Application Route: Intraperitoneal

**Tocopherol:** 

: LD50 (Rat): > 4.000 mg/kg Acute oral toxicity

Acute dermal toxicity LD50 (Rat): > 3.000 mg/kg

Assessment: The substance or mixture has no acute dermal

toxicity

Skin corrosion/irritation

Not classified based on available information.

Components:

**Tocopherol:** 

**Species** Rabbit

Method **OECD Test Guideline 404** 

Result No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

**Components:** 

**Tocopherol:** 

**Species** Rabbit

Method **OECD Test Guideline 405** 

Result No eye irritation

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Lynestrenol Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 4.2
 06.04.2024
 462442-00018
 Date of first issue: 15.01.2016

### Respiratory sensitisation

Not classified based on available information.

### **Components:**

**Tocopherol:** 

Test Type : Local lymph node assay (LLNA)

Exposure routes : Skin contact Species : Mouse

Method : OECD Test Guideline 429

Result : positive

Assessment : Probability or evidence of low to moderate skin sensitisation

rate in humans

Germ cell mutagenicity

May cause genetic defects.

**Components:** 

Lynestrenol:

Genotoxicity in vitro : Test Type: Chromosome aberration test in vitro

Result: positive

Test Type: sister chromatid exchange assay

Result: positive

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow

cytogenetic test, chromosomal analysis)

Species: Mouse

Application Route: Intraperitoneal injection

Result: positive

Test Type: sister chromatid exchange assay

Species: Mouse

Application Route: Intraperitoneal injection

Result: positive

Test Type: dominant lethal test

Species: Mouse

Application Route: Intraperitoneal

Result: positive

Germ cell mutagenicity- As-

sessment

Positive result(s) from in vivo somatic cell mutagenicity tests in

mammals. Evidence that the substance has potential to cause

mutations to germ cells

**Tocopherol:** 

Genotoxicity in vitro : Test Type: Chromosome aberration test in vitro

Method: OECD Test Guideline 473

Result: negative

Remarks: Based on data from similar materials

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Lynestrenol Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 4.2
 06.04.2024
 462442-00018
 Date of first issue: 15.01.2016

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

**Application Route: Ingestion** 

Result: negative

Remarks: Based on data from similar materials

### Carcinogenicity

Suspected of causing cancer.

### **Components:**

### Lynestrenol:

Species : Mouse
Application Route : Oral
Exposure time : 80 weeks
Result : positive

Tumor Type : breast tumors, Liver

Remarks : Benign and malignant tumor(s)

Species : Rat
Application Route : Oral
Exposure time : 80 weeks
Result : positive
Tumor Type : breast tumors

Carcinogenicity - Assess-

ment

Limited evidence of carcinogenicity in animal studies

### Tocopherol:

Species : Rat
Application Route : Ingestion
Exposure time : 104 weeks
Result : negative

Remarks : Based on data from similar materials

### Reproductive toxicity

May damage fertility. Suspected of damaging the unborn child.

### **Components:**

### Lynestrenol:

Effects on fertility : Test Type: Fertility/early embryonic development

Species: Rat, males Application Route: Oral

Fertility: LOAEL: 20 mg/kg body weight Remarks: Impaired spermatogenesis

Test Type: Fertility/early embryonic development

Species: Rat, females Application Route: Oral Fertility: LOAEL: 375 µg/kg

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Lynestrenol Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 4.2
 06.04.2024
 462442-00018
 Date of first issue: 15.01.2016

Result: Maternal toxicity observed., Effects on fertility

Test Type: Fertility/early embryonic development

Species: Rabbit Application Route: Oral Fertility: LOAEL: 1.300 µg/kg

Result: Effects on fertility, Postimplantation loss.

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rat

Application Route: Oral

Developmental Toxicity: LOAEL: 0,1 mg/kg body weight

Result: Effects on foetal development

Test Type: Embryo-foetal development

Species: Rabbit Application Route: Oral

Developmental Toxicity: LOAEL: 0,1 mg/kg body weight Result: Effects on foetal development, Postimplantation loss.

Reproductive toxicity - As-

sessment

Some evidence of adverse effects on development, based on animal experiments., Positive evidence of adverse effects on sexual function and fertility from human epidemiological stud-

ies.

**Tocopherol:** 

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rabbit

Application Route: Ingestion

Result: negative

Remarks: Based on data from similar materials

### STOT - single exposure

Not classified based on available information.

### STOT - repeated exposure

May cause damage to organs through prolonged or repeated exposure.

### **Components:**

Lynestrenol:

Target Organs : Blood, Mammary gland, Uterus (including cervix), Ovary
Assessment : Causes damage to organs through prolonged or repeated

exposure.

### Repeated dose toxicity

### **Components:**

**Tocopherol:** 

Species : Rat NOAEL : 500 mg/kg

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Lynestrenol Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 4.2
 06.04.2024
 462442-00018
 Date of first issue: 15.01.2016

Application Route : Ingestion Exposure time : 90 Days

Remarks : Based on data from similar materials

### **Aspiration toxicity**

Not classified based on available information.

### 11.2 Information on other hazards

### **Endocrine disrupting properties**

### **Product:**

Assessment : The substance/mixture does not contain components consid-

ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

### **Experience with human exposure**

### **Components:**

Lynestrenol:

Ingestion : Target Organs: Uterus (including cervix)

Target Organs: breasts Target Organs: ovaries Target Organs: Blood

Symptoms: Headache, Nausea, Abdominal pain, Rash, Dizziness, Tremors, Sweating, Vomiting, migraine, acne, breast tenderness, gynecomastia, menstrual irregularities, ovarian

cysts

Remarks: Used to prevent pregnancy

### **SECTION 12: Ecological information**

### 12.1 Toxicity

### **Components:**

**Tocopherol:** 

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

Remarks: Based on data from similar materials

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): > 23,53 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Remarks: No toxicity at the limit of solubility

Toxicity to algae/aquatic

plants

NOEC (Pseudokirchneriella subcapitata (green algae)): 25,8

mg/l

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Lynestrenol Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 4.2
 06.04.2024
 462442-00018
 Date of first issue: 15.01.2016

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility

EC50 (Pseudokirchneriella subcapitata (green algae)): > 25,8

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility

Toxicity to microorganisms : EC50 : > 937 mg/l

Exposure time: 30 min Method: ISO 8192

Remarks: Based on data from similar materials

Toxicity to fish (Chronic tox-

icity)

NOEC: > 100 mg/l Exposure time: 28 d

Species: Oncorhynchus mykiss (rainbow trout) Remarks: Based on data from similar materials

### 12.2 Persistence and degradability

### **Components:**

**Tocopherol:** 

Biodegradability : Result: Not readily biodegradable.

Biodegradation: 20 % Exposure time: 28 d

Method: OECD Test Guideline 301F

### 12.3 Bioaccumulative potential

No data available

### 12.4 Mobility in soil

No data available

### 12.5 Results of PBT and vPvB assessment

### **Product:**

Assessment : This substance/mixture contains no components considered

to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of

0.1% or higher.

### 12.6 Endocrine disrupting properties

### **Product:**

Assessment : The substance/mixture does not contain components consid-

ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Lynestrenol Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 4.2
 06.04.2024
 462442-00018
 Date of first issue: 15.01.2016

### **SECTION 13: Disposal considerations**

### 13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations.

According to the European Waste Catalogue, Waste Codes

are not product specific, but application specific.

Waste codes should be assigned by the user, preferably in

discussion with the waste disposal authorities.

Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

### **SECTION 14: Transport information**

### 14.1 UN number or ID number

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA : Not regulated as a dangerous good

### 14.2 UN proper shipping name

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA : Not regulated as a dangerous good

### 14.3 Transport hazard class(es)

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA : Not regulated as a dangerous good

### 14.4 Packing group

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Lynestrenol Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 4.2
 06.04.2024
 462442-00018
 Date of first issue: 15.01.2016

IMDG : Not regulated as a dangerous goodIATA (Cargo) : Not regulated as a dangerous goodIATA (Passenger) : Not regulated as a dangerous good

14.5 Environmental hazards

Not regulated as a dangerous good

14.6 Special precautions for user

Not applicable

14.7 Maritime transport in bulk according to IMO instruments

Remarks : Not applicable for product as supplied.

### **SECTION 15: Regulatory information**

# 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

Not applicable

Not applicable

REACH - Restrictions on the manufacture, placing on

the market and use of certain dangerous substances,

mixtures and articles (Annex XVII)

REACH - Candidate List of Substances of Very High :

Concern for Authorisation (Article 59).

REACH - List of substances subject to authorisation : Not applicable

(Annex XIV)

Regulation (EC) No 1005/2009 on substances that de- : Not applicable

plete the ozone layer

Regulation (EU) 2019/1021 on persistent organic pollu- : Not applicable

tants (recast)

Regulation (EU) No 649/2012 of the European Parlia: Not applicable

ment and the Council concerning the export and import

of dangerous chemicals

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of

major-accident hazards involving dangerous substances.

Not applicable

### Other regulations:

Note the Working Environment Act § 4-1 and § 4-2 on requirements for the employer to protect pregnant employees against discomfort and injury as a result of the work situation and the working environment.

Note the regulation on organization, leadership and participation, chapter 12 on the work of children and young people.

### The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Lynestrenol Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 4.2
 06.04.2024
 462442-00018
 Date of first issue: 15.01.2016

### 15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

### **SECTION 16: Other information**

Other information : Items where changes have been made to the previous version

are highlighted in the body of this document by two vertical

lines.

**Full text of H-Statements** 

H302 : Harmful if swallowed.

H317 : May cause an allergic skin reaction.

H340 : May cause genetic defects. H351 : Suspected of causing cancer.

H360Fd : May damage fertility. Suspected of damaging the unborn

child.

H372 : Causes damage to organs through prolonged or repeated

exposure.

Full text of other abbreviations

Acute Tox. : Acute toxicity
Carc. : Carcinogenicity
Muta. : Germ cell mutagenicity
Repr. : Reproductive toxicity

Skin Sens. : Skin sensitisation

STOT RE : Specific target organ toxicity - repeated exposure FOR-2011-12-06-1358 : Norway. Occupational Exposure limits

FOR-2011-12-06-1358 / : Long term exposure limit

TWA

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships: n.o.s. - Not Otherwise Specified: NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic sub-

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Lynestrenol Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 4.2
 06.04.2024
 462442-00018
 Date of first issue: 15.01.2016

stance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

### **Further information**

Sources of key data used to compile the Safety Data Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

Classification procedure:

cy, http://echa.europa.eu/

### Classification of the mixture:

# Muta. 1B H340 Calculation method Carc. 2 H351 Calculation method Repr. 1A H360Fd Calculation method STOT RE 2 H373 Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NO / EN